NANEXA — Nanexa AB Share News
0.000.00%
Last trade - 00:00- SEK2.01bn
- SEK1.95bn
- SEK36.15m
Brief: Nanexa Carries Out Directed Issue Of Units
Brief: Nanexa Comments On News About License On Long-Acting Technology Platform
Advisory: Alerts on Nanexa progress, revaluation and financing withdrawn
Brief: Nanexa Q2 EBIT SEK -6.124 Million
Brief: Nanexa Appoints Cecilia Danckwardt-Lillieström As New CFO
Brief: European Medicines Agency Approves Nanexa's Clinical Trial Application For Phase I Study With NEX-22
Brief: Nanexa Q1 EBIT SEK -3.363 Million
Brief: Nanexa Says Approval Of Clinical Trial Application For Nex-22 Study Delayed
Brief: Nanexa Proposes No Dividend For 2023
Brief: Nanexa Q4 Revenue SEK 6.816 Million
Brief: EMAValidates Nanexa's Clinical Trial Application For Of NEX-22
Brief: Nanexa Intends To Implement Cost Savings
Brief: Nanexa Signs Evaluation Agreement With Global Pharmaceutical Company
Brief: Nanexa Reports Preliminary Financial Information For Period January-September 2023
Brief: Nanexa Carries Out Rights Issue Of About SEK 121 Mln
Brief: Nanexa Is Granted Patent In India
Brief: Nanexa Q2 EPS at SEK -0.16
Brief: Nanexa Posts Positive Results From Preclinical Study Of NEX-22
Brief: Nanexa Says Nex-20 Phase 1 Study Confirms Controlled Release Of Lenalidomide